You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九強生物(300406.SZ):子公司與普瑞基準簽署框架協議 加深在基因測序檢測技術、免疫組化等技術與應用層面的全面合作
格隆匯 11-23 20:29

格隆匯11月23日丨九強生物(300406.SZ)公佈,公司控股子公司州邁新生物技術開發有限公司(“邁新”)普瑞基準科技(北京)有限公司(“普瑞基準”)於今日簽署普瑞基準與福州邁新框架協議》。

普瑞基準科技(北京)有限公司是一家以“數據驅動”為特色的腫瘤轉化醫學公司。公司在多組學(Multi-omics)技術、生物信息學、生物統計/機器學習、中心實驗室服務和伴隨診斷開發方面具備獨特而領先的技術。前公司已經與眾多國內外醫藥企業達成戰略合作,並開發多款行業領先的伴隨診斷產品。公司旗下的中心實驗室通過ISO9011、中國NCCL、歐洲EMQN和美國CAP 等質量認證,是國內癌症新藥研發轉化醫學研究的領先公司

服務內容如下: 2.1.甲乙雙方將在腫瘤藥物轉化等醫學研發領域充分發揮各自優勢,深化合作,共同推進雙方與藥物開發企業的合作,為藥物進入臨牀階段做好充分的準備極大提高抗癌藥物臨牀驗成功率,為藥企提供轉化醫學全新的研發服務模式;

2.2.各階段臨牀試驗中的中心實驗室檢測的合作;

2.3.共建分子診斷中心實驗室;

2.4.免疫組化產品應用開發合作與技術支持:包括不限於Claudin 18.2FRα EGFRAXL,為免疑義,前述款項指的是靶點與用藥相關性的檢測與評估;

2.5.NGS 測序技術及試劑盒的開發合作與技術支持;

2.6.協同開發伴隨診斷試劑盒;

2.7.通過整合雙方的數據庫,形成更豐富的癌症組學數據庫,並基於AIBERT平台進行數據挖掘與生物信息學分析

2.8.內部交流:本協議期間,甲乙雙方同意將在精準醫療學術及產業領域整合雙方的優勢資源,加強內部學術交流或內部產業研討,在不涉及各自公司核心利益的前提下雙方應積極為對方公司提供一定的技術指導和員工培訓,共同致力於拉動精準醫療學術及產業的發展。

此次合作,是為了充分利用甲乙雙方及甲乙雙方關聯公司在精準醫療領域的技術儲備和優勢,和各自行業內領先地位和行業影響力,加深雙方在基因測序檢測技術、免疫組化等技術與應用層面的全面合作,加速科研成果的臨牀轉化與應用,雙方一致同意建立長期、全面的戰略合作關係,推進前沿技術的探索和創新,助力精準醫療的持續創新,實現藥物研發領域的互相支持、互利合作、實現雙贏。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account